Results 31 to 40 of about 2,821 (202)
Frontiers in Medicine, 2022 To compare the efficacy and safety of different interventions [including antimuscarinics, mirabegron, OnabotulinumtoxinA, sacral neuromodulation (SNM) and peripheral tibial nerve stimulation (PTNS)] for treating idiopathic overactive bladder (OAB ...
Peng Liu +4 more
doaj +1 more source
Antimuscarinic actions of antihistamines on the heart [PDF]
Journal of Biomedical Science, 2006 Antimuscarinic side-effects, which include dry mouth, tachycardia, thickening of mucus possibly sedation, of the antihistamines limited the usefulness of these drugs. The advent of newer agents has reduced the sedative effect of the antihistamine. The data presented here show that one of the newest antihistamines, desloratadine, and a first generation ...
Huiling, Liu, Qi, Zheng, Jerry M, Farley
openaire +2 more sources
Antimuscarinics and lung cancer survival: A Norwegian population-based cohort study
, 2023 Objectives: Epidemiological studies have reported an association between antimuscarinics and reduced risk of cancer, including lung cancer (LC). However, the potential association between antimuscarinic use and LC prognosis has not previously been ...
Nathalie C Støer +11 more
core +1 more source
Urological Science, 2015 Objective: Mirabegron, a β3-adrenoceptor agonist, has been shown to be effective and safe in the treatment of overactive bladder (OAB). The aim of this study was to assess the efficacy and safety of mirabegron (50 mg) versus placebo in Taiwanese patients
Hann-Chorng Kuo +5 more
doaj +1 more source
THE SELECTIVE ANTIMUSCARINIC ACTION OF STERCURONIUM [PDF]
British Journal of Pharmacology, 1980 The antimuscarinic activity of stercuronium, a competitive neuromuscular blocking drug, has been compared in the anaesthetized guinea‐pig, guinea‐pig atria, bladder and ileum, rabbit atria and the sympathetically innervated rabbit ear artery preparation using carbachol (CCh) as agonist.In the anaesthetized guinea‐pig, stercuronium (0.2 and 2.0 μmol/kg)
C K, Li, F, Mitchelson
openaire +2 more sources
A Prospective, Comparative Study of the Occurrence and Severity of Constipation with Darifenacin and Trospium in Overactive Bladder [PDF]
Journal of Clinical and Diagnostic Research, 2015 Introduction: Darifenacin and trospium are the commonly used antimuscarinics in the management of overactive bladder (OAB). Constipation is the second most common treatment related sideeffect.
Revanna Manjunatha +3 more
doaj +1 more source
Adverse Events and Treatment Discontinuations of Antimuscarinics for the Treatment of Overactive Bladder in Older Adults: A Systematic Review and Meta-Analysis [PDF]
, 2017 Introduction Antimuscarinics should be used with caution in older adults with overactive bladder (OAB) due to anticholinergic adverse events (AEs). Systematic reviews and meta-analyses (SRMAs) have analyzed safety-related outcomes but have not specified ...
Kebodeaux, Clark D. +7 more
core +1 more source
Non‑Hormonal treatment of BPH/BOO
Indian Journal of Urology, 2014 Objectives: To review the use of non-hormonal pharmacotherapies in the treatment of lower urinary tract symptoms (LUTS) due to presumed benign prostatic hyperplasia (BPH).
Nadir I Osman +2 more
doaj +1 more source
Toxins, 2020 This study aimed to evaluate and compare the efficacy and safety of mid-urethral sling (MUS) with botulinum toxin A (BoNT-A) versus MUS only in women with mixed urinary incontinence.
Yi-Huei Chang +5 more
doaj +1 more source
Persistence of antimuscarinic drug use [PDF]
European Journal of Clinical Pharmacology, 2008 Evidence suggests antimuscarinic drugs for the overactive-bladder syndrome only confer modest improvements in quality of life. We wanted to describe the persistence of therapy, including an extended analysis beyond the 1-year follow-up employed in other studies.All prescriptions for drugs in ATC category G04BD were retrieved for the period 1999-2006 ...
Brostrøm, Søren, Hallas, Jesper
openaire +5 more sources